MedicaidPrior AuthMedium impact
Imaavy intravenous solution (nipocalimab-aahu) (New)
Humana·IN · Neurology, Internal Medicine, Pharmacy·Medicaid
Effective date
Aug 1, 2026
We identified it
Aug 4, 2026
Summary
Humana Medicaid (Indiana) has established a new prior authorization policy for Imaavy (nipocalimab-aahu), a monoclonal antibody for treating generalized myasthenia gravis (gMG) in anti-AChR or anti-MuSK antibody positive patients. Coverage requires confirmation of gMG diagnosis with specific antibody testing and documented trial or contraindication of pyridostigmine plus at least one immunosuppressive therapy. This is a brand-new coverage pathway effective August 1, 2026.
Action Required
By July 15, 2026: Billing team and providers must implement prior authorization procedures for Imaavy (nipocalimab-aahu) claims under Humana Medicaid Indiana. (1) Update billing software to route all Imaavy requests through prior auth workflow before claim submission. (2) Create authorization checklist requiring documentation of: diagnosis of gMG, confirmation of anti-AChR or anti-MuSK antibodies, and evidence of prior trial or contraindication of pyridostigmine AND at least one immunosuppressive agent (azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide). (3) Train neurology and specialty clinic staff on new requirements. (4) Ensure prior auth request includes specific antibody subtype to route correctly. (5) Reference Humana PAL system (www.humana.com/PAL) for applicable medical and procedural coding. Claims submitted without prior authorization will be denied; authorization required for initial and renewal periods (duration specified in policy but not stated in document).